Results 171 to 180 of about 128,460 (250)

Clinical Image-Based Dosimetry of Actinium-225 in Targeted Alpha Therapy. [PDF]

Cancers (Basel)
Ramonaheng K, Banda K, Qebetu M, Goorhoo P, Legodi K, Masogo T, Seebarruth Y, Mdanda S, Sibiya S, Mzizi Y, Davis C, Smith L, Ndlovu H, Kabunda J, Maes A, Van de Wiele C, Al-Ibraheem A, Sathekge M.   +17 more
europepmc   +1 more source

Four-year experience with an in-house treatment management platform to streamline departmental operations in radiation oncology. [PDF]

J Appl Clin Med Phys
Chang GN, Rong Y, Buckey C, Susen MJ, Lara PR, Lemish PR, Boutis GS, Chen Q, Clouser EL.   +8 more
europepmc   +1 more source

Dosimetry

Indian Journal of Nuclear Medicine, 2010
openaire   +1 more source

Eye Lens Radiation Exposure During TAVI: Current Evidence and Imaging-Based Strategies for Dose Reduction. [PDF]

Tomography
Zanon C, Fiocco A, Tarzia V, Quaia E.
europepmc   +1 more source

Revealing the interplay between flow dynamics and cavitation activity in a flow-through sonoreactor. [PDF]

Ultrason Sonochem
Javidani A, Poux M, Aubin J, Chaumat H, Barthe L.   +4 more
europepmc   +1 more source

An adapted methodology to characterize the neutron emission of californium neutron sources. [PDF]

Radiat Prot Dosimetry
Stabilini A, Geser FA, Kasprzak M, Mayer S.   +3 more
europepmc   +1 more source

Single-system outcomes after adopting yttrium-90 radioembolization with personalized dosimetry as the primary treatment approach for unresectable, solitary hepatocellular carcinoma. [PDF]

ESMO Gastrointest Oncol
Zamani A, Núñez K, Sandow T, Gimenez J, Cohen A, Thevenot P.   +5 more
europepmc   +1 more source

Phase 1 Study of [¹⁷⁷Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results. [PDF]

J Nucl Med
Mittra ES, Solnes LB, van der Veldt AAM, Wong J, Aloj L, Heinrich MC, Chen CT, Rowe SP, Brabander T, Pacey S, Aimone P, Pathak D, Blumenstein L, Liu Y, Iagaru A.   +14 more
europepmc   +1 more source

Radioembolization (90Y) achieves higher response rates and reduces progression risk compared with DEB-TACE in hepatocellular carcinoma. [PDF]

Hepatol Commun
Núñez K, Hasani N, Cronan J, Gimenez J, Cohen A, Sandow T, Thevenot P.   +6 more
europepmc   +1 more source

Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression. [PDF]

EJNMMI Res
Khreish F, Rosar F, Burgard C, Petto S, Maus S, Stemler T, Bartholomä M, Sabet A, Schaefer-Schuler A, Ezziddin S.   +9 more
europepmc   +1 more source